The absence of a significant association between LGALS3 gene variants and the inflammation markers levels suggested that it should be cautious when galectin‐3 was used as a therapeutic target for chronic inflammatory disorders, such as coronary artery disease. This evidence concerns the gene LGALS3 and coronary artery disorder.